U.s. food and drug administration accepts takeda's supplemental biologics license application for use of takhzyro® (lanadelumab-flyo) to prevent hereditary angioedema (hae) attacks in children 2 years of age and older

Cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food & drug administration (fda) has accepted a supplemental biologics license application (sbla) for the potential expanded use of takhzyro® (lanadelumab-flyo) for prophylaxis to prevent attacks of hereditary angioedema (hae) in pediatric patients 2 to
TAK Ratings Summary
TAK Quant Ranking